Long Term Survival Following High Dose Sequential Chemotherapy With Autologous Hematopoietic Cell Rescue For Multiple Myeloma
Year: 2010
Type: article
Abstract: High-dose therapy (HDT) with autologous hematopoietic cell rescue (AHCR) improves survival in patients with multiple myeloma, but is not curative due to a continuous risk of relapse. One approach to try to reduce relapse is to optimize pretransplant therapy and the preparative regimen. We investigated the outcome of sequential HDT with AHCR. Patients were initially treated with standard dose chemotherapy (primarily VAD) to maximum response. They then received cyclophosphamide 4 gm/m2 followed by G-CSF and peripheral blood hematopoietic cell collection by apheresis upon count recovery.
Authors: P. Doan, C. Gasparetto, J. Chute, M. Horwitz, D. Rizzieri, K. Sullivan, J. Edwards, R. Jacobson, K. Corbet, N. Chao, G. Long
Institutions: Duke Medical Center, AdventHealth
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $3,650
OpenAlex ID: W2164949196